Follow-on Offering

Healthcare
Follow-on Offering

Summary

Baird served as co-manager on this offering

About

Natera, Inc. (“Natera” or the “Company”) (NASDAQ-GS:NTRA) recently completed an underwritten public offering of 6,571,428 shares of its common stock at a price to the public of $35.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 857,142 shares of common stock. The gross proceeds to Natera from the offering are expected to be approximately $230 million before deducting the underwriting discounts and commissions.

Natera is a global leader in cell-free DNA testing. The mission of the Company is to change the management of disease worldwide with a focus on reproductive health, oncology and organ transplantation. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The Company offers proprietary genetic testing services to inform physicians who care for pregnant women, oncologists, and cancer researchers, including bio pharmaceutical companies and genetic laboratories through its cloud-based software platform. Natera is headquartered in San Carlos, California.
CONTACT US TO LEARN MORE
Healthcare
Follow-on Offering
Date
October 2019
Company
Natera, Inc.
Transaction
M&A
Sectors
Healthcare
Target Location
North America

Share